Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 in Refractory Hypertension
NCT00899977Phase 2Terminated
- Sponsor
- Targacept
- Start
- May 2009
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmecamylamine in hypertension (HTN) (5 arms), sponsored by Targacept. Primary endpoint: Mean difference between TC-5214 and placebo in change at 3 hours from baseline SBP. Started May 2009; status: terminated.
02
Drugs
dexmecamylamine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00899977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00899977.